SML3650

CTPI-2

≥98% (HPLC)

• Synonym(e): 2-(4-Chloro-3-nitrobenzenesulfonamido)benzoic acid, 2-[[(4-Chloro-3-nitrophenyl)sulfonyl]amino]benzoic acid, CTPI 2, CTPI2
• Empirische Formel (Hill-System): C₁₃H₉ClN₂O₆S
• CAS-Nummer: 68003-38-3
• Molekulargewicht: 356.74
• UNSPSC Code: 12352200
• NACRES: NA.25
• MDL number: MFCD00129907
• Assay: ≥98% (HPLC)
• Form: powder
• Quality level: 100

Eigenschaften

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: [S](=O)(=O)(Nc2c(cccc2)C(=O)O)c1cc(c(cc1)Cl)[N+](=O)[O-]
• InChI: 1S/C13H9ClN2O6S/c14-10-6-5-8(7-12(10)16(19)20)23(21,22)15-11-4-2-1-3-9(11)13(17)18/h1-7,15H,(H,17,18)
• InChI key: NJTHPOSQGFJTDP-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

CTPI-2 is a selective mitochondrial citrate transporter (SLC25A1) inhibitor that displays H1299 anti-proliferation activity in a SLC25A1-dependent manner (IC50 <10  μM). When compared with CTPI-1, CTPI-2 exhibits 20-fold higher target affinity (hSLC25A1 KD = 3.5 μM vs. 63.6 μM, respectively) and is ~1000-fold more potent against H1299 sphere-forming capacity. CTPI-2 inhibits mitochondrial respiration and formation of patient NSCLC tumors-derived CSCs spheres in cultures (10-50 μM), as well as suppresses the growth of patent-derived NSCLC exnografts in mice in vivo (28 mg/kg q.o.d. i.p.).

Selective mitochondrial citrate transporter (SLC25A1) inhibitor with anti-cancer efficacy in cultures and in vivo.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable